Paper Details

  1. Home
  2. Paper Details

[Daily ultrashort chemotherapy and intermittent short-term chemotherapy with 4 drugs of communicable pulmonary tuberculosis treated for the first time. Results of a cooperative multicenter study].

Author: BeckH, EuleH, EversH, FischerP, KwiatkowskiH, MerkelS, ReechR, SielerR, ThomasE, WeineckeW

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Three different tuberculosis treatment regimens were compared: a 3-month daily regimen, a 6-month twice-weekly regimen, and a two-phase 6-month regimen. The 3-month regimen was discontinued due to a high relapse rate. While all regimens showed good treatment success (94-100% negative cultures after treatment), relapse rates differed significantly: 19% for 3-month, 9% for two-phase 6-month, and 3% for 6-month twice-weekly. All regimens had acceptable tolerability, with common side effects like flu-like symptoms, elevated blood urea, and transient liver enzyme elevation, most of which were mild. These findings led to updated tuberculosis treatment recommendations and highlight the potential for further optimization of treatment regimens.
Paper Details　
Original Abstract of the Article :
Three short-course regimens, all comprising isoniazide (H), rifampicine (R), streptomycine (S) and pyrazinamide (Z), are compared in a randomized prospective cooperative clinical trial. The drugs are given daily in a 3-month regimen (3-HRSZ), twice a week in a 6-month regimen (6-HRSZ2), and in a fur...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/3532585

データ提供：米国国立医学図書館（NLM）

Tuberculosis Treatment: A Multi-center Study Comparing Short-Course Regimens

The field of tuberculosis treatment is a vast desert, with researchers constantly searching for the most effective and efficient way to combat this disease. This study, conducted in a cooperative multicenter setting, focuses on the effectiveness of different short-course regimens for pulmonary tuberculosis. The study involved three treatment groups: a 3-month regimen (3-HRSZ), a 6-month regimen (6-HRSZ2), and a two-phase 6-month regimen (3-HRSZ3/3-HSZ2). The researchers used a randomized prospective clinical trial design, which is like navigating a carefully planned route through the desert, ensuring that all participants have an equal chance of being assigned to any of the groups. This allowed them to compare the effectiveness of each regimen, and they found that the 3-month regimen had a higher relapse rate, which is like a sudden sandstorm interrupting your journey.

The Importance of Short-Course Regimens in Tuberculosis Treatment

The study found that the 6-month regimen (6-HRSZ2) had the lowest relapse rate (3%), which is a very promising outcome. This suggests that this regimen could be a more effective treatment option for tuberculosis, similar to finding a hidden oasis in the desert.

Implications for Tuberculosis Treatment and Patient Care

The researchers also observed that the 6-month regimen had good tolerability, with minimal side effects. This is important, as it shows that the regimen is not only effective but also safe for patients. This is like finding a comfortable campsite in the desert, where you can rest and recover from your journey.

Dr. Camel's Conclusion

This multi-center study provides valuable insights into the effectiveness of different short-course regimens for pulmonary tuberculosis. It highlights the importance of finding the right balance between effectiveness and tolerability. The 6-month regimen (6-HRSZ2) emerged as a promising treatment option, offering a chance to combat tuberculosis with minimal side effects. This study, like a well-mapped desert route, guides us toward a better understanding of tuberculosis treatment, paving the way for further research and improved patient care.

Date :
  1. Date Completed 1986-11-18
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

3532585

DOI: Digital Object Identifier

3532585

SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.